

Reproducible hepatoprotective effects and clinical translatability of semaglutide in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH

Authors
Michael Feigh, Denise Oró, Nicolas Eskesen, Jacob Nøhr-Meldgaard, Henrik H. Hansen

Gubra, Hørsholm, Denmark

Corresponding author
Michael Feigh - mfe@gubra.dk


Background & Aim

The glucagon-like-peptide (GLP)-1 analogue semaglutide is currently approved for the treatment of type 2 diabetes and obesity. Semaglutide has been reported to promote benefits on histological outcomes in MASH patients (Newsome et al., NEJM, 2020) and is currently in phase 3 clinical trial (ESSENCE) for MASH. The present study aimed to evaluate robustness of therapeutic outcomes of semaglutide treatment in the translational GAN diet-induced obese (DIO) mouse model of biopsy-confirmed MASH and fibrosis.


Methods

Semaglutide was profiled in 8 individual GAN DIO-MASH mouse studies with identical design. C57BL/6J mice were fed the GAN diet high in saturated fat, fructose, and cholesterol for 34-40 weeks before treatment start. Only animals with biopsy-confirmed MASH (NAS \geq 5) and fibrosis (stage \geq F1) were included and stratified into treatment groups. GAN DIO-MASH mice (n=14-18 per group) received semaglutide (Sema, 30 nmol/kg, SC) or vehicle (Veh, SC) once daily for 12 weeks. Vehicle-dosed chow-fed controls served as healthy controls (Lean). Within-subject comparisons (pre- vs. post-treatment) were performed for NAS and fibrosis stage by GHOST. Terminal quantitative endpoints included plasma/liver biochemistry and AI-based quantitative liver histology. Furthermore, histopathological pre-to-post assessment of NAS and fibrosis stage were evaluated against primary histological endpoints applied in a corresponding clinical trial, (i.e. resolution of MASH with no worsening of liver fibrosis; at least 1-stage fibrosis improvement without worsening of MASH). Statistical analyses were performed using Dunnett's test one-factor linear model (individual studies), Fisher's exact test (pooled study data on semiquantitative histopathological scoring variables) or one-way ANOVA with Dunnett's post-hoc test (pooled study data on quantitative endpoints), respectively. *p<0.05, **p<0.01, ***p<0.001 compared to corresponding vehicle controls.


1 Study outline




2 Body weight




3 Liver weight & transaminases




4 Plasma total cholesterol & triglycerides




5 NAFLD Activity Score (NAS) & Fibrosis stage



6 Quantitative histological markers of steatosis, inflammation, fibrosis and fibrogenesis



7 Clinical translatability



Conclusion

- + Semaglutide was characterized in 8 individual studies in GAN DIO-MASH mice
- + Semaglutide reduced body weight and consistently improves hepatomegaly, transaminases and hypercholesterolemia
- + Semaglutide reproducibly improves NAFLD Activity Score (NAS), primarily by reducing steatosis score
- + Semaglutide does not improve Fibrosis Stage.
- + Benefits on histopathological scores were supported by quantitative histology for steatosis, inflammation and fibrogenesis.
- + Histological outcomes in GAN DIO-MASH mice are comparable to the corresponding clinical trial for semaglutide (Newsome et al. NJEM 2020)



Scan the QR code to see the poster online
www.gubra.dk